Arq - The Hyper Intelligent Investment Engine By Angel Broking

Company Research Reports

Company Reports

Result Updates | May 09th 2017

Alembic Pharmaceuticals Ltd

CMP : 593Target Price : 648

Alembic Pharma posted marginally lower than expected results for 4QFY2017. In Rupee terms, revenues grew by 17.8% yoy to `737cr (`770cr expected) v/s `626cr in 4QFY2016. In sales terms, the company posted growth on the back of international formulations, which grew by 44% yoy, while the Indian domestic formulations grew by 6.0% yoy. On th..

View As PDF

Result Updates | May 09th 2017

Sanofi India Ltd

CMP : 4,181Target Price : 4,181

For 1QCY2017, Sanofi India posted results which were below expectations on all fronts. The sales came in at `513cr v/s. `550cr expected, registering a yoy de-growth of 1.1%. On the operating front, the EBITDA margin came in at 12.0% (17.6% expected) v/s. 17.7% in 1QCY2016. Despite better GPM (Gross Profit Margin), which came in at 54.2% v..

View As PDF

Sort By

Result Updates | May 02nd 2017

Wipro Ltd

CMP : 494
Target Price : 570

For 4QFY2017, Wipro’s revenues in IT services came in at US$1,955mn (v/s US$1,937mn expected) v/s US$1,903mn in 3QFY2017, a 2.7% qoq growth, with a 1.7% qoq growth in Constant Currency (CC). In Rupee terms, revenues grew by 2.2% qoq to `13,988cr (v/s `13,561cr expected) v/s `13,688cr in 3QFY2017. On the operating front, EBIT margin came i..

Result Updates | Apr 24th 2017

Tata Consultancy Services Ltd

CMP : 2,311
Target Price : 2,651

For 4QFY2017, TCS posted revenue of US$4,452mn v/s US$4,470mn expected, with 1.5% qoq growth mostly volume led, which was 1.7% qoq. Revenue in Constant Currency (CC) terms came in at 1.0% qoq. In Rupee terms, revenues de-grew by 0.3% qoq to Rs29,642cr v/s Rs29,996cr expected, led by Rupee appreciation. On the operating front, EBIT came in..

Result Updates | Apr 24th 2017

HDFC Bank Ltd

CMP : 1,533
Target Price : 1,650

After some moderation in business growth HDFC Bank is back with strong momentum during the quarter. We believe strong internal capital generation will drive 20% earnings CAGR over FY17-19, which will be backed by stable NIM and moderating credit cost. At the current market price, the bank is trading at 3.3x FY2019E ABV. We Maintain ACCUMU..

Result Updates | Apr 19th 2017

Infosys Ltd

CMP : 922
Target Price : 1,179

For 4QFY2017 the results of Infosys were below expectations, on the sales front the company has posted revenue of US$2,569mn v/s expectations of US$2,589mn, with 0.7% qoq growth. On CC (constant Currency) terms, the revenues have remained flat qoq. The volume growth during the period came in at 1.2% qoq. On the operating margins front, th..

Initiating Coverage | Mar 31st 2017

Karur Vysya Bank Ltd

CMP : 110
Target Price : 140

Karur Vysya Bank (KVB) is one of the oldest private sector banks with strong presence in the Southern parts of India. More than 53% of KVB’s 706 branches are located in Tamil Nadu, however it is gradually branching out in other parts of India also. KVB’s earnings were impacted due to higher provisions and lower business growth, however, w..

Initiating Coverage | Mar 27th 2017

Navin Fluorine International Limited

CMP : 2,957
Target Price : 3,650

Navin Fluorine (NFIL), part of the Arvind Mafatlal group, is a leader in fluorine based chemicals in India. It operates mainly in four segments i.e. Refrigerant, Organic Fluoride, Specialty Chemicals and CRAMs. While Refrigerant segment will continue to generate strong cash flows, the incremental focus of the company is the high margin an..

Result Updates | Mar 10th 2017

Sanofi India Ltd

CMP : 4,301
Target Price :

For 4QCY2016, Sanofi India posted results which were below expectations on the sales front. The sales came in at Rs552cr v/s. Rs570cr expected, posting a yoy growth of 5.6%. On the operating front, the EBITDA margin came in at 12.2% (12.3% expected) v/s. 12.7% in 4QCY2015. This came in-spite of GPM (Gross Profit Margin), which came in at ..

Initiating Coverage | Mar 09th 2017

Natco Pharma Ltd

CMP : 786
Target Price : 926

Natco Pharma is a Hyderabad based pharma company with focus on limited competition and high margin products. It has presence in domestic and global markets and has two main business segments i.e. API and Formulations. Natco’s topline and bottomline is set to grow at 36% and 61% CAGR over FY16-FY19E due to 1) strong performance of domestic..

Result Updates | Mar 06th 2017

Dishman Pharmaceuticals and Chemicals Ltd

CMP : 222
Target Price : 143

Dishman Pharmaceuticals posted results lower than expected for 3QFY2017, with sales at Rs356cr v/s. Rs386cr in 3QFY2016, down by 7.6% yoy, mainly on the back of CRAMS. CRAMS sales (Rs246.7cr) de-grew by 16.5% yoy, constituting 69.2% of sales in 3QFY2017; while others (Rs110cr) posted a growth of 21.2% yoy. On the operating front, the gros..

Initiating Coverage | Mar 03rd 2017

Repco Home Finance Ltd

CMP : 642
Target Price : 825

REPCO Home Finance is a midsized Housing Finance Company (HFC), with focus on the underserved self-employed segment. While the current operations of the company are predominately concentrated in Southern market (90%), the management intends to gradually venture into other geographies over the next 5 years. The target segment of REPCO is h..